Bone destruction in multiple myeloma

被引:29
作者
Matsumoto, Toshio [1 ]
Abe, Masahiro [1 ]
机构
[1] Univ Tokushima, Grad Sch Hlth Biosci, Dept Med & Bioregulatory Sci, Tokushima 7708503, Japan
来源
SKELETAL DEVELOPMENT AND REMODELING IN HEALTH, DISEASE, AND AGING | 2006年 / 1068卷
关键词
bone resorption; osteoclast; receptor-activator of NF-kappa B (RANK) ligand; osteoprotegerin; macrophage inflammatory protein-1; osteopontin; vascular endothelial growth factor (VEGF); interleukin-6; vascular cell adhesion molecule (VCAM)-1; angiogenesis; bone formation; osteoblast; Wingless-type (Wnt); secreted Frizzled-related protein (sFRP); dickkopf (Dkk);
D O I
10.1196/annals.1346.035
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 [理学]; 0710 [生物学]; 09 [农学];
摘要
Multiple myeloma (MM) is characterized by accumulation of monoclonal plasma cells in the bone marrow and progression of lytic bone lesions. MM cells enhance bone resorption by triggering a coordinated increase in RANK ligand and decrease in osteoprotegerin in the bone marrow. Macrophage inflammatory protein (MIP)-1 alpha and (MIP)-1 beta are secreted by MM cells, and play a major role in the enhancement of bone resorption by MM cells. Furthermore, the growth and survival of MM cells are enhanced by contact with osteoclasts (OCs) suggesting the presence of a vicious cycle between OCs and MM cells. OCs also enhance angiogenesis in concert with MM cells largely through the cooperative actions of osteopontin from OCs and VEGF from MM cells. The angiogenic effect may further facilitate the vicious cycle between bone destruction and MM cell expansion. In addition, MM cells secrete soluble factor(s) to suppress bone formation. Secreted Frizzled-related protein (sFRP)-2, an inhibitor of Wingless type (Wnt) binding to Frizzled, is produced by most MM cells, and immunodepletion of sFRP-2 abrogates the inhibition of bone formation. Thus, MM cells enhance bone resorption and suppress bone formation to cause destructive bone lesions. Further elucidation of the mechanism of bone destruction by MM may lead to a novel therapeutic approach to prevent bone destruction and tumor growth.
引用
收藏
页码:319 / 326
页数:8
相关论文
共 11 条
[1]
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion [J].
Abe, M ;
Hiura, K ;
Wilde, J ;
Shioyasono, A ;
Moriyama, K ;
Hashimoto, T ;
Kido, S ;
Oshima, T ;
Shibata, H ;
Ozaki, S ;
Inoue, D ;
Matsumoto, T .
BLOOD, 2004, 104 (08) :2484-2491
[2]
Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma [J].
Abe, M ;
Hiura, K ;
Wilde, J ;
Moriyama, K ;
Hashimoto, T ;
Ozaki, S ;
Wakatsuki, S ;
Kosaka, M ;
Kido, S ;
Inoue, D ;
Matsumoto, T .
BLOOD, 2002, 100 (06) :2195-2202
[3]
[Anonymous], 1998, J Clin Oncol, V16, P3832
[4]
Multiple myeloma [J].
Bataille, R ;
Harousseau, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (23) :1657-1664
[5]
High bone density due to a mutation in LDL-receptor-related protein 5 [J].
Boyden, LM ;
Mao, JH ;
Belsky, J ;
Mitzner, L ;
Farhi, A ;
Mitnick, MA ;
Wu, DQ ;
Insogna, K ;
Lifton, RP .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (20) :1513-1521
[6]
Choi SJ, 2000, BLOOD, V96, P671
[7]
Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines [J].
Damiano, JS ;
Cress, AE ;
Hazlehurst, LA ;
Shtil, AA ;
Dalton, WS .
BLOOD, 1999, 93 (05) :1658-1667
[8]
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development [J].
Gong, YQ ;
Slee, RB ;
Fukai, N ;
Rawadi, G ;
Roman-Roman, S ;
Reginato, AM ;
Wang, HW ;
Cundy, T ;
Glorieux, FH ;
Lev, D ;
Zacharin, M ;
Oexle, K ;
Marcelino, J ;
Suwairi, W ;
Heeger, S ;
Sabatakos, G ;
Apte, S ;
Adkins, WN ;
Allgrove, J ;
Arslan-Kirchner, M ;
Batch, JA ;
Beighton, P ;
Black, GCM ;
Boles, RG ;
Boon, LM ;
Borrone, C ;
Brunner, HG ;
Carle, GF ;
Dallapiccola, B ;
De Paepe, A ;
Floege, B ;
Halfhide, ML ;
Hall, B ;
Hennekam, RC ;
Hirose, T ;
Jans, A ;
Jüppner, H ;
Kim, CA ;
Keppler-Noreuil, K ;
Kohlschuetter, A ;
LaCombe, D ;
Lambert, M ;
Lemyre, E ;
Letteboer, T ;
Peltonen, L ;
Ramesar, RS ;
Romanengo, M ;
Somer, H ;
Steichen-Gersdorf, E ;
Steinmann, B .
CELL, 2001, 107 (04) :513-523
[9]
Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1α and MIP-1β correlates with lytic bone lesions in patients with multiple myeloma [J].
Hashimoto, T ;
Abe, M ;
Oshima, T ;
Shibata, H ;
Ozaki, S ;
Inoue, D ;
Matsumoto, T .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) :38-41
[10]
Novel therapies targeting the myeloma cell and its bone marrow microenvironment [J].
Hideshima, T ;
Chauhan, D ;
Podar, K ;
Schlossman, RL ;
Richardson, P ;
Anderson, KC .
SEMINARS IN ONCOLOGY, 2001, 28 (06) :607-612